• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

One Drug Stopped Progression Of Many Types Of Cancer In Small Trial

March 25, 2023 by Deborah Bloomfield

ATX-101 is an experimental drug designed to kill cells of all types of cancers, while leaving healthy cells untouched. A trial of cancer patients for whom all existing treatments had failed was intended just to test ATX-101’s safety. For many of those participating it appears to have extended their lives, halting the progression of their disease for months or years.

If someone claims to have a “cure for cancer” you can usually safely assume it’s a scam. Cancer isn’t one disease. The wide variety of types have distinct causes, varying symptoms, and affect different parts of the body. We’ve made spectacular progress against some of these, very little against others. It doesn’t make much sense to think a single treatment will cure everything.

Advertisement

ATX-101 isn’t likely to represent a universal cancer cure, but the results of its Phase I trial, reported in a new study, suggest the dream might not be as ridiculous as previously thought. By targeting a feature common to cancer cells in different organs the drug may reveal a crucial point of vulnerability for all forms of the disease. If so, future drugs could attack this weak spot with ever greater precision.

“Cancer cells are more stressed than other cells. However, they don’t die but continue to grow even when they are damaged,” said Professor Marit Otterlei, of the Norwegian University of Science and Technology, in a statement. “Conventional cancer treatment with chemotherapy puts more stress on the cancer cells so that the cells eventually do die.” 

Unfortunately, chemotherapy also damages healthy cells, so there is only so much that can be given before the cure becomes worse than the disease. An increasing array of drugs target cancer cells in other ways, but only work on a single sort of cancer, or at best a few types.

Otterlei’s solution was to look for molecules that only affect cells that show cancer’s specific form of stress, and have no effect on others. ATX-101 is the first she has found that performs well enough in vitro and in animal studies to be tried in humans.

Advertisement

“ATX-101 can be used as the only treatment. It can stabilize the cancer as shown in the recently published studies, but the medicine can also help chemotherapy work even better so that you don’t have to have so much of it,” Otterlei said.

For the trial, 25 patients with a variety of cancers were given ATX-101 intravenously in one of four doses. Even at the highest dosage none of the patients found the treatment intolerable, and most reported only mild side-effects, such as itching around the site of the infusion.

Half the patients had received at least four different treatments prior to enrolment in the trial, and in almost all cases all had not worked or had stopped working. Twelve responded well enough over six weeks that they extended their participation. Eight of these experienced a substantial pause in the progression of the disease; for one, the cancer was no larger 29 months later. The sample size was far too small to determine if some forms of cancer are more susceptible than others.

Otterlei’s breakthrough was to discover a binding sequence, which she named APIM, that regulates stress in cells, binding to the PCNA coordinator molecule when pressures are high. It’s taken her 18 years from finding APIM to the two Phase 2 trials currently being conducted against sarcomas and ovarian cancer, respectively.

Advertisement

To do that Otterlei and colleagues needed to make an APIM-containing drug that binds to PCNA and prevents it from interacting with proteins, disrupting the cancerous cells to their destruction while apparently leaving healthy cells alone. ATX-101 can also re-sensitize cancer cells that have developed resistance to standard chemotherapies, restoring the effectiveness of treatments that were no longer working.

In the process of her cancer research Otterlei accidentally discovered a potential new class of antibiotics.

 The study is published in Oncogene (open access).

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Exclusive-China’s Miniso to double U.S. stores, add NY ‘flagship’ as pandemic slashes mall rents
  2. Indian food delivery giant Swiggy in talks to raise funds at over $10 billion valuation
  3. Soccer-Rashford receives honorary doctorate from University of Manchester
  4. Myth Or Magic: Duck Quacks Don’t Echo

Source Link: One Drug Stopped Progression Of Many Types Of Cancer In Small Trial

Filed Under: News

Primary Sidebar

  • 2024 Saw Higher Levels Of Carbon Dioxide In The Atmosphere Than Ever Before
  • Halloween Fireballs Will Grace Our Skies As The Taurid Meteor Showers Arrive
  • Newly Discovered Hunting Megastructures Suggest Pre-Bronze Age Societies More Sophisticated Than Previously Thought
  • What Is Spectroscopy And Why Is It So Important To Science?
  • Parkinson’s “Trigger” Seen For The First Time: Scientists Image The Toxic Molecules Inside The Human Brain
  • What Flying Animals Exist That Are Not Birds?
  • DNA Evidence Uncovers Surprising Origins Of Native Americans
  • Single Gene Swap “Transfers A Behavior” Between Two Species For The First Time
  • Interstellar Object 3I/ATLAS Has A Rare “Anti-Tail”, New Observations Confirm
  • Asteroid Apophis: Animation Shows Asteroid’s Nail-Biting Close Approach To Earth In 2029
  • Titan Breaks A Key Chemistry Rule: What That Means For Alien Life
  • Scientists Studied “Chicago Rat Hole” – They Have Bad News, The South Atlantic’s Magnetic Field Weak Spot Is Growing, And Much More This Week
  • Could This Be The Real Reason Humans Survived And Neanderthals Died Out?
  • Newly Discovered Snail Species Named After Studio Ghibli Co-Founder Is A Hairy Beauty
  • 2025 SC79 Is The Second-Fastest Asteroid Ever Found – And Only The Second Within Venus’ Orbit
  • When Red Devil Spiders Arrived On A New Island, Their Genome Dramatically Shrank In Half
  • Is This The World’s Oldest Story? Ancient Human Tale About The Seven Sisters May Be From 100,000 BCE
  • This Pill Is Actually A Tiny Printer That Repairs Internal Injuries Using Biocompatible Ink
  • “This Is Amazing”: Scientists Have Found Evidence Of A Long-Lost World Deep Within The Earth
  • From The Shiniest World To Lava And Eternal Darkness, These Are The Weirdest Known Planets
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version